Pilot Study of Biomarkers for Radiation Therapy

Paused

Conditions studied: Cancer

In brief

The purpose of this study is to determine whether specific assays of DNA damage repair proteins can be used in patients undergoing radiation therapy. The ultimate goal of this research is to develop clinically useful biomarkers from blood samples that could be used to customize radiation treatment for individuals, leading to reduced side effects and improved outcomes.

Key facts

Study ID

NCT01050725

Run by

Benaroya Research Institute

People needed

100

Starts

2009-11-01

Last updated by the study team

2011-06-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients > 18 years of age with primary lung, esophageal or rectal cancer receiving neo-adjuvant chemoradiotherapy before planned resection
• patients with clinically localized prostate cancer receiving definitive radiation therapy with external beam treatment. brachytherapy as a boost and/or hormonal therapy are allowed.
• patients with head and neck, lung, esophageal or cervical cancer who will receive definitive radiotherapy

You may not qualify if…

• prior history of chemotherapy given within 6 months before enrollment.
• prior radiotherapy or radionuclide treatment and/or brachytherapy within 6 months prior to enrollment.
• unwillingness to comply with tests, protocol, or informed consent.
• concurrent enrollment on any protocol that would require non-compliance with treatment procedures.
• chemotherapy required within 2 hours following first dose of XRT.
• PET scan done within 48 hours of first blood draw.
• nuclear medicine exposure within 4 days prior to first draw.

Where it is running

• Virginia Mason Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.